Literature DB >> 29132555

Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.

Benjamin Powers1, Tuya Pal2, Christine Laronga3.   

Abstract

Technological advances realized through next-generation sequencing technologies coupled with the loss of the ability to patent genes have led to reduction in costs for genetic testing. As a result, more people are being identified with inherited breast cancer syndromes that may affect recommendations for surveillance and risk reduction. Surgeons, at the forefront for patients newly diagnosed with breast cancer, must keep current with the changing landscape of genetics to continue to provide appropriate counsel and care. This article provides an overview of individuals at risk for inherited cancer predisposition and recommendations for surveillance and management.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Germline mutation; Inherited breast cancer syndromes; Personalized medicine; Surgical considerations

Mesh:

Year:  2018        PMID: 29132555     DOI: 10.1016/j.soc.2017.08.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

Review 1.  Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).

Authors:  Danielle A Henry; Marie C Lee; Deanna Almanza; Kamran A Ahmed; Weihong Sun; David C Boulware; Christine Laronga
Journal:  Breast Cancer Res Treat       Date:  2018-11-24       Impact factor: 4.872

2.  Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.

Authors:  Margaret Waltz; Anya E R Prince; Julianne M O'Daniel; Ann Katherine M Foreman; Bradford C Powell; Jonathan S Berg
Journal:  J Genet Couns       Date:  2020-01-22       Impact factor: 2.537

Review 3.  Multi gene panel testing for hereditary breast cancer - is it ready to be used?

Authors:  Andreea Catana; Adina Patricia Apostu; Razvan-Geo Antemie
Journal:  Med Pharm Rep       Date:  2019-07-31

4.  Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.

Authors:  Jacob G Comeaux; Julie O Culver; John E Lee; Danielle Dondanville; Heather L McArthur; Emily Quinn; Nicholas Gorman; Charité Ricker; Ming Li; Caryn Lerman
Journal:  Mol Genet Genomic Med       Date:  2022-08-25       Impact factor: 2.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.